Loading clinical trials...
Loading clinical trials...
Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag
Conditions
Interventions
Eltrombopag (ELT)
Locations
13
Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Heraklion, Crete, Greece
Novartis Investigative Site
Shatin, Hong Kong
Start Date
October 15, 2013
Primary Completion Date
February 23, 2022
Completion Date
February 23, 2022
Last Updated
December 30, 2022
NCT06805097
NCT02158936
NCT01235988
NCT01055600
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions